/

Business

Daniel Carcillo’s Wesana Health Raises $4 Million to Expand Psychedelic Research

,
Wesana Health, founded by former NHL star Daniel Carcillo, has raised $4 million to continue its psychedelic research for traumatic brain injuries.

MindMed Stock Catalysts for 2021: NASDAQ, Clinical Trial Results and More (MMED / MMEDF)

In today's episode, we discuss :MindMed Stock Catalysts for 2021: NASDAQ, Clinical Trial Results and More (MMED / MMEDF). 2020 was a wild year for MindMed, with the company IPOing in March, at just over 20c/ share, all prices in American currency. Then, the MindMed stock price shot up to a high of $4.37 in December, only to fall about 30% and consolidate around $3 a share in the new year. But what will be the main catalysts for MindMed and its stock going forward in 2021? Put another way, what are the events and dates that shareholders and potential investors should circle on their calendars? In this episode, we are going to talk about several catalysts to look out for 1. MindMed's Nasdaq uplisting - When to expect MindMed to join the Nasdaq? - Is MindMed's uplisting a sure thing? -What will happen to MindMed stock if/when the company gets uplisted? 2. Clinical trials wrapping up, and data being released by MindMed - Important dates MindMed investors should circle in their calendars 3. MindMed's quarter end financial reporting 4. MindMed conference calls Unknown Catalysts for Mindmed: 1. Clinical trials expansions 2. Financial agreements ** Also, on the 20th of January, Kevin O'Leary and Jr Rahn went live discussing MindMed. For those who haven't seen it, Jr mentioned a few extra catalysts we should be looking forward to which we will discuss in our next episode. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com https://www.prnewswire.com/news-releases/atai-life-sciences-announces-closing-of-125-million-series-c-financing-round-301178915.html DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed #MMED #MMEDF

Is MindMed Expanding to PSILOCYBIN? (BIG MMED / MMEDF Stock NEWS)

In today’s episode, we will be covering some Massive MindMed news that broke on January 14th that lead me to believe that MindMed might be expanding to psilocybin. Mindmed stock, MMED on the Canadian NEO market, and MMEDF on the American OTC market led with a press release entitled "MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience". MindMed revealed that the company has added a scientist named Robert Barrow as their Chief Development Officer. Tucked away in this news release about a hiring decision is a quote which points to a future MindMed project And that project will be researching the effects of Psilocybin So up until now, MindMed has focused all their phase 2 trials on LSD and 18-MC, which is a derivative of Ibogaine, while leaving treating maladies with psilocybin to other companies like Compass Pathways (NASDAQ:CMPS). So, Barrow is bringing with him to MindMed intimate knowledge about the efficacy of psilocybin in treating MDD, as well as dosing data and regime set up. MindMed (MMED/MMEDF) has some phase 1 trials looking at the safety of psilocybin in conjunction with the Liechti Lab at the University Hospital Basel and is also comparing psilocybin to LSD in a phase 1 trial. MindMed also has a licence to test psilocybin. However, MindMed has yet to start a trial specifically looking at psilocybin as a medicine.. So does this mean that MindMed's hiring decision is related to the company's plans on expanding their clinical trial pipeline to include a psilocybin treatment, sometime in the future? If that speculation turns out to be true, that decision will further expand MindMed's potential product pipeline as well as the MindMed stock. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed #MMED #MMEDF

MindMed Expands MICRODOSING trials (BIG MMED/MMEDF stock UPDATE)

In today's episode "MindMed Expands Microdosing Trials", we'll discuss a Big MindMed Stock Update. On January 12th, MindMed ticker symbol (NEO: MMED ) and (OTC:MMEDF) put out a Press Release entitled MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers. In other words, MindMed is expanding its LSD microdosing studies from just looking at how they can help those with adult ADHD, to how they could affect a more general population. This is BIG news the MindMed team and us shareholders. As I mentioned in one of our previous episodes : "Why I'm More Excited About MindMed's 18-MC than its LSD treatments", MindMed has a diverse pipeline with other experiential drugs such as LSD for anxiety and psilocybin to treat ADHD. And If these trials come back successful, it'll be the beginning of more LSD microdosing studies for MindMed. In this episode, we will do three things: 1:We'll read the Press Release and discuss what it means, in layman's terms 2: We'll enter the Speculation Zone to discuss the potential effects of this move 3: We'll discuss how this expansion affects MindMed stock as an investment So, what does this all mean for investors? Can we assume that MindMed’s LSD microdosing to treat ADHD trial is going well? This, even without the new trials, would be very good news for us long term investors. Moreover, this new study shows that MindMed is continuing to expand their potential product pipeline which will also look great for the MMED/ MMEDF Stock. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/ DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed #MMED #MMEDF
Psychedelic Business News Spotlight: January 15, 2021

Psychedelic Business News Spotlight: January 15, 2021

This week in psychedelic business news, IPOs, employee stock options, mergers, research, and more.

Why Psychedelic Stocks are NOT Cannabis 2.0 (Huge MindMed Stock Opportunity)

In today’s episode, we will be discussing why Psychedelic Stocks, like MindMed (MMED / MMEDF) and Compass Pathways (CMPS) are not Cannabis 2.0, and why psychedelic stock prices will not follow the same path. For those who remember, Pot Stocks skyrocketed on the news of legalization, and then quickly tumbled back down to earth. Some have dismissed companies like MindMed (MMED/MMEDF) and Compass Pathways (CMPS) as just the cannabis hype 2.0. This, however, could not be further from the truth. To be clear stocks like, MindMed Stock ( MMED : NEO market) and (MMEDF : OTC market), and Compass Pathways stock, ticker symbol CMPS are nothing like cannabis stocks. To explain why, we are going to discuss an article entitled , “Why The Psychedelics Market is not Cannabis 2.0”, written by Jeff Siegel. Psychedelic stocks are comparables to biotech companies these days. The prospect of promising research is pushing valuations upwards There are plenty of psychedelic stocks have experienced triple-digit returns in the last twelve months: MindMed Stock MMED/MMEDF): 864% Numinuss Wellness (NUMI): 555% Revive Therapeutics (RVV): 166% Compass Pathways (CMPS): 88% The psychedelic industry is only just commencing. Other psychedelic stocks will soon penetrate the market and early investors can benefits from the shroom boom with 10X to 20X gains. #psychedelicstocks #shroomstocks #mindmedstock https://www.benzinga.com/markets/cannabis/21/01/19008810/why-the-psychedelics-market-is-not-cannabis-2-0 Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

Is Compass Pathways a GOOD INVESTMENT? (CMPS stock analysis)

In this episode, we take a deep dive into Compass Pathways (CMPS), a psychedelic-medicines company aiming to treat depression with psilocybin. To understand Compass Pathways (CMPS ), as a company and as an investment, you have to study 5 things: What problem is Compass Pathways trying to solve? CMPS’ clinical trial, treating depression with psilocybin The founders and leaders of Compass Pathways Compass’ Financials Is CMPS stock a good investment for a retail investor? As the psychedelic stocks sector takes off, Compass Pathways, alongside MindMed (MMED / MMEDF), looks poised to lead the pack. No other psychedelic-medicines company is as advanced in a clinical trial as is Compass Pathways (CMPS). CMPS has a phase 2b trial to test the effectiveness of psilocybin in treating Treatment-Resistant Depression could be game changing, and make for a great investment opportunity. Let me know in the comments what you guys think. Is Compass Pathways a GOOD INVESTMENT? Will the CMPS stock skyrocket in 2021? Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. Resources: https://compasspathways.com/ https://www.webmd.com/depression/understanding-depression-basics#1 https://www.psychiatry.org/patients-families/depression/what-is-depression https://www.nimh.nih.gov/health/statistics/major-depression.shtml https://www.webmd.com/depression/guide/depression-treatment-options#1 https://www.ncbi.nlm.nih.gov/books/NBK361016/#:~:text=Inotherwordsantidepressantsare,foundtobeequallyeffective https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2222-4#:~:text=Treatmentresistantdepression(TRD),MDDpatientpopulation1 https://www.beckleyfoundation.org/psilocybin-for-depression-2 https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows https://compasspathways.com/our-research/psilocybin-therapy/about-psilocybin-therapy/#from-subnav https://psychedelicreview.com/person/ekaterina-malievskaia/ https://compasspathways.com/team-member/george-goldsmith/ https://compasspathways.com/team-member/lars-christian-wilde/ https://www.reuters.com/article/us-compass-pathways-ipo/peter-thiel-backed-compass-pathways-files-for-u-s-ipo-idUSKBN25O31T https://www.globenewswire.com/news-release/2019/05/15/1825506/0/en/Anxiety-Disorder-and-Depression-Treatment-Market-To-Reach-USD-18-90-Billion-By-2026-Reports-And-Data.html https://www.treehugger.com/facts-about-magic-mushrooms-4868810 https://psychedelicreview.com/person/ekaterina-malievskaia/ #CompassPathways #CMPS #PsychedelicStocks #MindMed #MMED #MMEDF #PsychedelicStocks #ThePsychedelicInvestor
Psychedelic Business News

Psychedelic Business News Spotlight: January 08, 2021

This week in psychedelic business news, Mydecine, Neon Mind, Ehave, and more.
NeonMind Takes Psilocybin Therapy Public

NeonMind Takes Psilocybin Therapy Public

NeonMind is the latest psychedelic company to go public. It's the first to launch on the Canadian Stock Exchange in 2021.

© 2023 Psychedelic Spotlight. | Owned and operated by PSYC Media Corporation, Inc. a US publicly traded company (OTCPink: PSYC) | All Rights Reserved.